Background
Care of patients with glomerulonephritis [GN] is a significant burden on the healthcare system. As reported by ANZDATA 1 , GN is the leading cause of end stage renal disease [ESRD] for those patients that survive to go onto renal replacement therapy [ figure 1 ]. CKD.QLD 2 , a registry of patients with precursor stages of kidney disease, reports a prevalence of 12% for those patients referred to the public state renal services [ figure 2 ].
Internationally, GN registries have been established to further the understanding, and ultimately improve, patient clinical outcomes 3, 4 .
There is a paucity of data pertaining to the spectrum of GN in Australia, supporting the formation of a registry.
Aims
▪ To establish a registry for biopsy-proven glomerulonephritis [GN] , commencing in Queensland, Australia.
▪ To provide a dataset that will enable prospective research into the epidemiology, clinical course, prognostic indicators and treatment of GN in the Australian setting.
▪ Ultimately, the objective is to collaborate nationally and internationally to form a broader renal biopsy registry program, supporting research endeavors.
Methods
▪ Demographic, clinico-pathological and therapeutic information is planned to be collected from patients with biopsy-proven GN, commencing with collaborative public renal services within Queensland Health.
▪ Data will be collected at time of renal biopsy and at intervals thereafter, with endpoints of dialysis-dependence, transplantation, death or withdrawal from registry. 
Conclusion
The QLD.GN registry, the first of its kind in Australia, will provide a robust, transparent and real-time dataset capable of improving patient care, supporting observational research in GN. Furthermore, the dataset may facilitate identification of key patient populations for recruitment into clinical trials. The registry will be a nucleus from which affiliations will grow.
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